Lexaria says DehydraTECH 3.0 retatrutide tablet boosts absorption up to 4,552% in dog study

PUBT · 2d ago
Lexaria says DehydraTECH 3.0 retatrutide tablet boosts absorption up to 4,552% in dog study
  • Lexaria reported dog-study PK results showing higher oral absorption for amycretin and retatrutide using its DehydraTECH 3.0 formulations.
  • Best amycretin DHT3.0 tablet delivered 1.65% absolute bioavailability, up 481.14% versus the DHT2.0 reference tablet.
  • The same amycretin result more than doubled a 0.7% absolute bioavailability level reported in a separate Novo Nordisk primate study.
  • Best retatrutide DHT3.0 tablet raised absorption 4,552.2% versus the DHT2.0 reference tablet; absolute bioavailability reached 0.1%.
  • Top retatrutide DHT3.0 capsules reached 0.26% absolute bioavailability, supporting partnering outreach for oral next-generation GLP-1 drugs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608240910ACCESSWRNAPR_____1210744) on August 24, 2026, and is solely responsible for the information contained therein.